TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with type 1 diabetes mellitus for at least 24 months~* usage of daily insulin treatment~* random serum C-peptide concentration \< 0.5 ng/mL~Exclusion Criteria:~* pregnant or nursing~* HbA1c \>9.0%~* renal insufficiency~* hepatic synthetic insufficiency~* aspartate or alanine aminotransferase \> 3 times the upper limit of normal~* hematocrit less than or equal to 30%~* use of \> 2.0 U/kg total insulin dose per day~* inadequate bilateral venous access in both arms~* congestive heart failure, New York Heart Association class II, III or IV~* active malignancy within 5 years, except basal cell or squamous cell skin cancers~* history of breast cancer or malignant melanoma~* major surgical operation within 30 days~* current seizure disorder.~* current bleeding disorder, treatment with warfarin, or platelet count below 50,000~* history of pheochromocytoma or disorder with increased risk of pheochromocytoma~* history of insulinoma~* history of glycogen storage disease.~* positive for HIV, hepatitis C virus or active hepatitis B virus infection~* whole blood donation of 1 pint (500 mL) within 8 weeks~* active substance or alcohol abuse~* administration of glucagon within 28 days~* participation in other studies involving an investigational drug or device within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- G-Pen first, then Lilly Glucagon (Type: OTHER): A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection \[rDNA origin\])
- Lilly Glucagon first, then G-Pen (Type: OTHER): A single 1 mg SC injection of Lilly Glucagon (glucagon injection \[rDNA origin\]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Weight 50-100 kg~Exclusion Criteria:~* Chronic disease~* Concomitant drug use~* Pregnancy or lactation~* Fasting glucose \>6 mmol/L.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide 0.6 mg/day subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 24 weeks 0 days-28weeks 6 days by best obstetrical estimate~* \<72 h age~* Positive pressure ventilation for at least 1 hour duration during the first 72 hours of life~* Presence of indwelling intravenous line for drug administration~Exclusion Criteria:~* Any patient judged to be non-viable or for whom withdrawal of life support is planned~* Patients with major lethal congenital anomalies~* Triplets or higher order multiples~* Patients delivered for maternal indications (low risk of Ureaplasma colonization)~* Patients with EKG QT interval corrected for heart rate (Qtc) ≥ 450 ms~* Patients with significant hepatic impairment (direct bilirubin \>1.5 mg/dL)~* Patients exposed to other systemic macrolide~* Patients with clinically suspected Ureaplasma central nervous system (CNS) infection or other confirmed bacterial/viral infection~* Patients participating in other clinical trials involving investigational products.

- Gender: ALL
- Minimum Age: 2 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Placebo (5% dextrose) (Type: PLACEBO_COMPARATOR): Placebo
- Azithromycin (Type: EXPERIMENTAL): Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Statin Therapy and COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years old with a PCR or immunological confirmation of Covid-19 infection, admitted in the hospital for at least 24 hours, will be included.~Exclusion Criteria:~* Patients \< 18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- with statins (Type: None): Covid-19 infected patients with statins
- without statins (Type: None): Covid-19 infected patients without statins

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females ≥ 18 years of age and \< 65 years.~2. Unilateral or bilateral primary carcinoma of the breast confirmed.~3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.~4. Clinically measurable tumor size who are candidates for neoadjuvant therapy.~5. No evidence of distant metastasis.~6. Normal renal and liver functions.~7. Non-diabetics.~Exclusion Criteria:~1. Pregnant or breastfeeding women.~2. Prior cancer chemotherapy.~3. Heart disease or reduced cardiac output with left ventricular ejection fraction \< 50%.~4. Metastatic breast cancer patients.~5. Patients with hepatic impairment.~6. Patients with renal impairment.~7. Diabetics.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metformin group (Type: EXPERIMENTAL): Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
- Control group (Type: ACTIVE_COMPARATOR): Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Dopamine and Initial Graft Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Donors:~* Brain death confirmed~* Given consent to organ donation~* Current s-creatinine \< 2mg/dl~* On admission s-creatinine \< 1.3mg/dl~Recipients:~* Age over 18 years~* Placed on the waiting list~* Organ allocation according to ET standards~Exclusion Criteria:~Donors:~* Application of dopamine/dobutamine/adrenaline~* Application of noradrenaline \> 0.4µg/kg\*min~* Hemodynamic instability~Recipients:~* Refusal to participate in study /data analysis~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the age of 18 and 70 years, inclusive, at time of enrollment.~* Subject has never received antiviral treatment for hepatitis C virus (HCV) infection.~* Body mass index (BMI) is ≥ 18 to \< 38 kg/m\^2. BMI is calculated as weight measured in kilograms (kg) divided by the square of height measured in meters (m).~* Chronic HCV genotype 1-infection for at least 6 months prior to study enrollment.~* Subject has plasma HCV RNA level \> 10,000 IU/mL at screening~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any drug.~* Females who are or plan to become pregnant or breastfeeding or males whose partner is pregnant or planning to become pregnant.~* Recent history of drug or alcohol abuse that could preclude adherence to the protocol.~* Positive test result for hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibodies.~* Any current or past clinical evidence of cirrhosis (e.g., ascites, esophageal varices), or a liver biopsy or FibroTest/aspartate aminotransferase to platelet ratio (APRI) or FibroScan® showing cirrhosis or extensive bridging fibrosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV (Type: EXPERIMENTAL): ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
- ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV (Type: EXPERIMENTAL): ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with acne vulgaris and at least 20 but no more than 40 inflammatory lesions, 25-70 non-inflammatory lesions, no more than 2 nodules on the face~* Baseline IGA score of mild, moderate or severe~* Women of child-bearing potential must agree to use an effective method of birth control during the study and for 30 days after their final study visit~Exclusion Criteria:~* Any dermatologic condition or other medical problem that could interfere with clinical evaluation or requires the use of topical or systemic therapy that make evaluations and lesion count inconclusive~* Female subjects who are pregnant, nursing, or considering becoming pregnant~* Methemoglobin \> 2% at baseline~* Clinically significant anemia at baseline~* Use of topical or systemic medications to treat acne~* Use of medications that make acne worse, associated with methemoglobinemia, or nitric oxide donors

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- NVN1000 1% Gel (Type: EXPERIMENTAL): NVN1000 1% Gel twice daily
- NVN1000 4% Gel (Type: EXPERIMENTAL): NVN1000 4% Gel twice daily
- Vehicle Gel (Type: PLACEBO_COMPARATOR): Vehicle Gel twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants~* less than or equal to 32 weeks of gestational age~* appropriate for gestational age~* enterally fed with pasteurized breast milk

- Gender: ALL
- Minimum Age: None
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- rhBSSL (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, age at least 18 years at the time of signing informed consent~* Type 2 diabetes subjects clinically diagnosed at least 6 months prior to screening~* Treatment with stable daily dose (for at least 90 days prior to screening) of: - Metformin (equal or above 1000 mg or maximum tolerated dose documented in the patient medical record) and - Sulfonylurea - and willing to discontinue any other oral antidiabetic drugs containing insulin secretagogues, DPP4i (dipeptidyl peptidase-4 inhibitor), SGLT2 (sodium glucose co-transporter 2), colesevelam, bromocriptin and/or combination products at randomisation~* Insulin-naïve. Short term insulin treatment for acute illnesses for a total of 14 days or less is allowed as is prior insulin treatment for gestational diabetes~* HbA1c (glycosylated haemoglobin) 7.0-9.5 % (both inclusive) analysed by central laboratory~* Willing to consume 3 main meals daily (morning, mid-day and evening) throughout the entire trial. The definition for 'main meal' will be according to the investigator's discretion~Exclusion Criteria:~* Anticipated initiation or change in concomitant medications known to affect weight or glucose metabolism, in excess of 14 days (i.e. sibutramine, orlistat, thyroid hormones, systemic corticosteroids and other weight loss/modifying agents)~* Impaired liver function, defined as ALT (alanine aminotransferase) at least 2.5 times upper limit of normal (central laboratory value measured at screening visit)~* Inadequately treated high blood pressure defined as Class 2 hypertension or higher (i.e. systolic blood pressure equal to or above 160 mm Hg or diastolic equal to or above 100 mm Hg) in accordance with the National High Blood Pressure Education Program, 7th Joint National Committee1 and ESH/ESC 2013 Guidelines2~* Within the past 180 days prior to randomisation, any of the following: Myocardial Infarction, stroke or hospitalization for unstable angina and /or transient ischemic attack

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp (Type: EXPERIMENTAL): None
- IGlar + IAsp (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The subject cannot be enrolled in the study before all of the following inclusion criteria (including test results) are met:~1. Subject is between 18-55 years of age.~2. Subject meets the following Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of BED:~3. Subject has a BED diagnosis.~4. Subject's BED is of at least moderate severity with subjects reporting at least 3 binge eating days per week.~5. Female subjects must have a negative serum B-HCG pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements.~Exclusion Criteria:~Subjects are excluded from the study if any of the following exclusion criteria are met:~1. Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.~2. Subject is receiving psychotherapy (eg, supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) or weight loss support (eg, Weight Watchers) for BED.~3. Subject has used psychostimulants to facilitate fasting or dieting as a part of their BED.~4. Subject has a lifetime history of psychosis, mania, hypomania, dementia, or ADHD.~5. Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.~6. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.~7. Subject has a history of moderate or severe hypertension.~8. Subject is female and pregnant or nursing.~9. Subject has had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD489 (Lisdexamfetamine dimesylate) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV positive~2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)~Exclusion Criteria:~1. Not on cART and a CD4 \<500 at the time of screening~2. Patients on cART for \>6 months with a HIV viral load \>400 copies~3. Disallowed co-medication that cannot be stopped or replaced~4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic well-controlled HBV (HBV-DNA \<below the limit of detection) is allowed if fibroscan excludes \>F1 fibrosis~5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse transcriptase inhibitors and an allowed third agent which can be raltegravir (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Grazoprevir/elbasvir single tablet regimen (100/50mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Children eligible to be enrolled in the study were those~* whose parents provide written informed consent;~* were in generally good health based on the clinical judgment of the investigators;~* subjects were 22-45 months of age at the time of enrollment into V59P22E1;~* subject who had participated in the parent V59P22 study.~Exclusion Criteria:~Main exclusion criteria:~* Subjects with serious, acute, or chronic illnesses~* Subjects who had received any other licensed vaccines within 28 days (Exception: Influenza vaccine was allowed up to 14 days prior to and no less than 14 days after the study immunization) prior to enrolment and any study visit~* Subjects who had received any Meningococcal vaccine since the study dose of MenACWY or Men C at 12 months of age in V59P22 trial.

- Gender: ALL
- Minimum Age: 22 Months
- Maximum Age: 45 Months
- Healthy Volunteers: f

Study Arms:
- MenACWY (2 primary + 1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
- MenACWY (1 primary + 1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
- MenC (1 primary dose)+MenACWY (1 booster dose) (Type: EXPERIMENTAL): Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* TC:220～270mg/dl~* Male: 40-70 years old/ female: postmenopausal-70 years old~* \<40kg in weight~Exclusion Criteria:~* FH~* History of CHD(angina, MI, post-PTCA/CABG, etc.)~* History of CVA(stroke, TIA, etc.)~* Underlying malignant tumor

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete